Press release
Lizhuo Pharmaceutical Technology: (1R,2R)-(-)-1,2-CYCLOHEXANEDICARBOXYLIC ACID CAS NO. 46022-05-3
Short Description:Image: https://www.abnewswire.com/upload/2025/01/629886dc3482ac27657fe73f795a1a23.jpg
Product Name:(1R,2R)-(-)-1,2-CYCLOHEXANEDICARBOXYLIC ACID
CAS NO.:46022-05-3
Synonyms:
Lurasidone intermediate 6
Related Categories:pharmaceutical intermediates; intermediates; lurasidone intermediates; API intermediates; organic intermediates;
Appearance: White to Off-White solid
Purity: 98%
Application: lurasidone intermediates
Supply Ability: (1R,2R)-(-)-1,2-CYCLOHEXANEDICARBOXYLIC ACID CAS NO.46022-05-3 is our regularly production product, whether you need small sample or a large cargo of more than tonnage, our company can supply it formally
Company Profile
Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. is a subsidiary of Shenzhen Rich Chemical Technology Co., Ltd., located in Shanghai. Since its establishment, Lizhuo Pharmaceutical has been committed to providing global pharmaceutical companies and new drug research and development institutions with comprehensive solutions from early product development to drug listing. R&D, customization and production services of pharmaceutical intermediates and APIs required in the life cycle.
Lizhuo Pharmaceutical is a comprehensive technology enterprise focusing on the R&D, production and sales of pharmaceutical intermediates, mainly developing and producing anti-tumor, psychotropic, antiviral, hypoglycemic and antibacterial pharmaceutical intermediates. Our company also engaged in developing innovative drug intermediates according to the situation of the new drug market, and at the same time, develop and customize new drug intermediates according to the needs of customers.
Company Culture
Lizhuo Pharmaceutical has always adhered to the principle of "keeping promises and honoring promises" and the business philosophy of "excellence, continuous improvement, innovation and development, openness and sharing", striving to provide professional and fast technology and production services, and striving to be a first-class pharmaceutical intermediate and API companies.
Our company has a complete R&D, pilot and scale-up production base. Currently, we have one 1,000-square-meter R&D laboratory, 2 pilot production workshops in Wuhan, equipped with twenty 50L-1000L reactors, high and low temperature Circulation device (-40 degrees C-200 degrees C), ultra-low temperature reaction device (-120 degrees C), vacuum and atmospheric distillation tower (2-6 meters), molecular distillation, solid distillation and other advanced equipment, can undertake ultra-low temperature reaction, format Continuous reaction, nitration reaction, nitro reduction reaction, epoxidation synthesis reaction, solid-liquid distillation and rectification and other production processes, the research and development center can undertake the customization of pharmaceutical intermediates from grams to kilograms, and the pilot production workshop and factory can Produce hundreds of kilograms to tons of products.
The researchers of Lizhuo Pharmaceutical are all doctoral and master technicians who have been engaged in the pharmaceutical synthesis business for many years. They have certain research and achievements in the technical field, and they also have rich practical experience in engineering amplification. At the same time, we also cooperate with Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, School of Pharmacy, Zhejiang University, School of Pharmacy, Zhejiang University of Technology and other institutions to develop projects, so as to promote the research and development of new drugs faster and better, and have achieved a number of research results.
Media Contact
Company Name: Shanghai Lizhuo Pharmaceutical Technology Co.,Ltd.
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lizhuo-pharmaceutical-technology-1r2r12cyclohexanedicarboxylic-acid-cas-no-46022053]
Country: China
Website: https://www.shlzpharma.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lizhuo Pharmaceutical Technology: (1R,2R)-(-)-1,2-CYCLOHEXANEDICARBOXYLIC ACID CAS NO. 46022-05-3 here
News-ID: 3818939 • Views: …
More Releases from ABNewswire
Patio Elegance Brings Commercial-Grade Outdoor Kitchens and European Wellness De …
Patio Elegance establishes new standards for outdoor living by offering exclusively commercial-grade products built for decades of performance. The comprehensive collection spans professional kitchen islands and grills, authentic Lithuanian saunas, therapeutic cold plunges and jacuzzis, elegant gazebos, entertainment mancaves, and premium furniture all unified by European design excellence and institutional durability.
The outdoor living industry has long suffered from a quality gap, with most residential products failing to deliver the durability…
Andatel Grande Patong Phuket: Full Renovation Complete, Reopens Late March 2026
Andatel Grande Patong Phuket property: 122-room hotel across three buildings with iconic Olympic-size pool between two guest buildings, completely renovated after six-year COVID closure addressing extensive mold damage, all rooms 24 square meters with identical furniture/design.
PATONG, Phuket, Thailand - One of the best Andatel Grande Patong Phuket option in Phuket that is booked on Booking.com, Agoda, Hotels.com and more with free cancellation until 48 hours of check-in date that doesn't…
Insulin Resistance Pipeline 2025: Therapies Under Investigation, Clinical Trials …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Insulin Resistance pipeline constitutes 8+ key companies continuously working towards developing 10+ Insulin Resistance treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Insulin Resistance Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Insulin Resistance Market.
The Insulin Resistance Pipeline report embraces…
Caliente Brands Targets Niche Spice Market with Hickory-Smoked Beef Jerky Line F …
Caliente Brands, LLC capitalizes on growing consumer demand for authentically spicy snacks with a specialized beef jerky line that puts heat first. Using only 100% USDA Approved Beef and hickory smoking techniques, the veteran-owned company offers distinctive flavors including innovative Spicy Birria alongside traditional options, all designed to deliver the brand promise that smoky and spicy meet delicious.
Caliente Brands, LLC has strategically positioned itself to serve a niche but substantial…
More Releases for Lizhuo
Lizhuo Pharmaceutical Technology: Empagliflozin Intermediate 3 CAS NO. 1279691-3 …
Product Name:Empagliflozin Intermediate 3
Image: https://www.abnewswire.com/upload/2025/02/244d490e8e67be1fc6fd489f30405e07.jpg
CAS NO.:1279691-36-9
Synonyms:
Empagliflozin N-1;
(2S,3R,4S,5S,6R)-2-(3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)-4-chlorophenyl)-tetrahydro-6-(hydroxyMethyl)-2-Methoxy-2H-pyran-3,4,5-triol;
Methyl 1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]Methyl]phenyl]-alpha-D-glucopyranoside;
Related Categories:Empagliflozin intermediates; pharmaceutical raw materials; pharmaceutical intermediates; organic intermediates.
Appearance: White to Off-White solid
Purity: 98%
Application: Empagliflozin intermediates;pharmaceutical intermediate
Supply Ability
Empagliflozin Intermediate3 CAS NO.1279691-36-9 is our regularly production product, whether you need small sample or a large cargo of more than tonnage, our company can supply it formally
If you are interested in Empagliflozin Intermediate3 CAS NO.1279691-36-9, feel freely contact us please, and we will provide…
Lizhuo Pharmaceutical: 2,3,4,6-TETRA-O-PIVALOYL-ALPHA-D-GLUCOPYRANOSYL BROMIDE C …
Short Description:
Image: https://www.abnewswire.com/upload/2025/01/5582634c0519d11908763e506fa28cb3.jpg
Product Name: 2,3,4,6-TETRA-O-PIVALOYL-ALPHA-D-GLUCOPYRANOSYL BROMIDE
CAS NO.: 81058-27-7
Synonyms:
Canagliflozin Intermediate 3
TETRAKIS(2,2-DIMETHYLPROPANOATE)-A-D-GLUCOPYRANOSYL BROMIDE
Related Categories: Pharmaceutical intermediates, pharmaceutical raw materials, canagliflozin intermediates
Application
Canagliflozin intermediates, it can be used to prepare canagliflozin. Canagliflozin is the first FDA-approved SGLT2 inhibitor drug, which can lower blood sugar by breaking down glucose and excreting it through the kidneys, and is used to treat type 2 diabetes in adults
Supply Ability
2,3,4,6-TETRA-O-PIVALOYL-ALPHA-D-GLUCOPYRANOSYL BROMIDE CAS NO.81058-27-7 is our regularly production product, whether…
Lizhuo Pharmaceutical: 5-Chloro-2-((R)-5-Methyl-[1,4]diazepan-1-yl)benzooxazole …
Name: 5-Chloro-2-((R)-5-Methyl-[1,4]diazepan-1-yl)benzooxazole hydrochloride CAS NO. 1266664-66-7
Image: https://www.abnewswire.com/uploads/0d2bc98b28f1135e0a2afbf8a4e8a0ac.png
Short Description:Product Name:5-Chloro-2-((R)-5-Methyl-[1,4]diazepan-1-yl)benzooxazole hydrochloride
CAS NO.:1266664-66-7
Synonyms: Suvorexant Intermediate V
(R)-5-Chloro-2-(5-methyl-[1,4]diazepan-1-yl)-benzoxazole hydrochloride
Related Categories:Pharmaceutical raw materials; Suvorexan intermediates
Appearance: white to off-white solid
Application: Pharmaceutical raw materials; Suvorexan intermediates
Supply Ability: 5-Chloro-2-((R)-5-Methyl-[1,4]diazepan-1-yl)benzooxazole hydrochloride CAS NO.1266664-66-7 is our regularly production product, whether you need small sample or a large cargo of more than tonnage, our company can supply it formally
Contact Information: If you are interested in 5-Chloro-2-((R)-5-Methyl-[1,4]diazepan-1-yl)benzooxazole hydrochloride CAS NO.1266664-66-7, feel freely…
Lizhuo Pharmaceutical Technology: Benzylidene-bis(tricyclohexylphosphine)dichlor …
Short Description:
Product Name: Benzylidene-bis(tricyclohexylphosphine)dichlororuthenium
CAS NO. : 172222-30-9
Similar Name(Other name): Bis-(tricyclohexylphosphine)-benzylidenerutheniumRelated Categories: catalyst,precious metal catalyst,Ru catalyst
Image: https://www.abnewswire.com/uploads/a5101098765ea6d81099714a024e7408.png
Application
Benzylidene-bis(tricyclohexylphosphine)dichlororuthenium is a ruthenium catalyst. Ruthenium catalysts have strong tolerance to polar monomers, and can polymerize many polar monomers to prepare cycloolefin copolymers. Cycloolefin copolymers can be widely used in the manufacture of various optical, information, electrical, and medical materials.
Supply Ability
Benzylidene-bis(tricyclohexylphosphine)dichlororuthenium CAS NO.172222-30-9 is our regularly production product, whether you need small sample or big…
Lizhuo Pharmaceutical Technology: 2-(2H-1,2,3-TRIAZOL-2-YL)-5-METHYLBENZOIC ACID …
Short Description:
Product Name: 2-(2H-1,2,3-TRIAZOL-2-YL)-5-METHYLBENZOIC ACID
CAS NO.:956317-36-5
Synonyms:
Suvorexant Intermediate II;
5-Methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid;
Benzoic acid, 5-methyl-2-(2H-1,2,3-triazol-2-yl)-;
Related Categories:Pharmaceutical raw materials; intermediates; Suvorexan intermediates; organic chemical raw materials; pharmaceutical raw materials
Image: https://www.abnewswire.com/uploads/51ada473d01ce68eef9379ef699a6399.png
Product Information:
Name: 2-(2H-1,2,3-TRIAZOL-2-YL)-5-METHYLBENZOIC ACID
CAS NO.: 956317-36-5
Molecular Formula: C10H9N3O2
Molecular Weight: 203.2
MDL No.:MFCD18382679
EINECS: 689-732-5
M.P.:174-176
B.P.: 413
Density: 1.35 g/cm3(Predicted)
Refractive Index:N.A.
F.P.:204
Storage condition: Sealed in dry,Room Temperature
Appearance: White to Light yellow solid
Purity: 98%
Application: Pharmaceutical raw materials; intermediates; Suvorexan intermediates; organic chemical raw materials; pharmaceutical raw materials
Supply Ability: 2-(2H-1,2,3-TRIAZOL-2-YL)-5-METHYLBENZOIC ACID CAS NO.956317-36-5 is…
Lizhuo Pharmaceutical Has Focused on the Research And Development of Pharmaceuti …
Since its establishment, Lizhuo Pharmaceutical [https://www.shlzpharma.com/] has focused on the research and development of pharmaceutical intermediates, mainly developing and producing anti-tumor, psychotropic, antiviral, hypoglycemic and antibacterial pharmaceutical intermediates. Our company will also develop innovative drug intermediates according to the situation of the new drug market, and at the same time, develop and customize new drug intermediates according to the needs of customers.
Customized Service Scope
1. Functional materials and pharmaceutical intermediates
2. Synthesis…
